Magnitude 7.9 Quake Cut into Simcere Pharmaceutical’s First-half Earnings; Company “Very Close” To First Round Of Acquistions
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The massive 7.9 magnitude earthquake that ripped through southwestern China three months ago also cut into Simcere Pharmaceutical's earnings for the first half of 2008, according to senior management at the Nanjing-based company
You may also be interested in...
Simcere Enters Co-development Partnership With San Francisco Biotech Outfit On Monoclonal Antibody Treatment, Scans China For Takeover Targets
BEIJING - While reporting a strong rise in earnings for 2008, the leaders of China's Simcere Pharmaceutical Group said they have signed a co-development deal with a San Francisco biotech firm on a monoclonal antibody treatment for cancer
Simcere Enters Co-development Partnership With San Francisco Biotech Outfit On Monoclonal Antibody Treatment, Scans China For Takeover Targets
BEIJING - While reporting a strong rise in earnings for 2008, the leaders of China's Simcere Pharmaceutical Group said they have signed a co-development deal with a San Francisco biotech firm on a monoclonal antibody treatment for cancer
Simcere Reports Positive Phase IV Interim Results For Lung Cancer Drug Endu
SHANGHAI - Simcere Pharmaceutical reported positive interim results for Phase IV clinical trials of its recombinant human endostatin lung cancer drug Endu, the company announced Sept. 3